Market capitalization | €1.97b |
Enterprise Value | €2.83b |
P/E (TTM) P/E ratio | 17.27 |
EV/FCF (TTM) EV/FCF | 24.80 |
EV/Sales (TTM) EV/Sales | 2.39 |
P/S ratio (TTM) P/S ratio | 1.66 |
P/B ratio (TTM) P/B ratio | 3.25 |
Dividend yield | 2.47% |
Last dividend (FY24) | €0.90 |
As a Free StocksGuide user, you can view scores for all 6,807 stocks worldwide.
3 Analysts have issued a Dermapharm forecast:
3 Analysts have issued a Dermapharm forecast:
Dec '24 |
+/-
%
|
||
Revenue | 1,181 1,181 |
4%
4%
|
|
Gross Profit | 397 397 |
13%
13%
|
|
EBITDA | 309 309 |
3%
3%
|
EBIT (Operating Income) EBIT | 219 219 |
3%
3%
|
Net Profit | 114 114 |
82%
82%
|
In millions EUR.
If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.
Dermapharm Holding SE engages in the development, manufacture. and market of patent-free pharmaceutical products. The company also involves in in-house development, in-house production, and distribution of pharmaceuticals and other healthcare products. It offers its products through the following brands: Dekristol 20,000 I.E., bite away, Herpotherm, sikapur, Ampho-Moronal, Solacutan, Ciclocutan, Minoxicutan, Prednisolut, Dienovel, Lactofem, Finapil, Panthenol-Augensalbe JENAPHARM, and Suxilep. The company was founded in 1991 and is headquartered in Grunwald, Germany.
Head office | Germany |
CEO | Hans-Georg Feldmeier |
Employees | 3,600 |
Founded | 1991 |
Website | www.dermapharm.de |
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.